BJMO - volume 10, issue 3, october 2016
B. Neyns MD, PhD
The initial use of immune checkpoint blockade was mainly limited to a fraction of physicians involved in the treatment of malignant melanoma. With the proof of principle and efficacy established in this disease process, these agents were being extensively investigated in other malignancies including lung cancer, renal cell carcinoma, gastric cancer, bladder cancer, ovarian cancer, and hematologic malignancies. Early results from some of these investigations are extremely encouraging and will likely lead to more indications in addition to the approved indications for the treatment of malignant melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma. It is therefore essential that the oncology community is aware of immune-related adverse events (irAEs), to recognize them in a timely fashion and be well-versed with their management. To discuss the specific toxicity profile associated with these agents, we consulted Prof. Dr. Bart Neyns, melanoma specialist at the UZ Brussel, with a vast experience in the use of immune-checkpoint inhibitors.
Read moreBJMO - volume 8, issue 5, november 2014
B. Neyns MD, PhD
(BELG J MED ONCOL 2014;8(4):171–6)
Read moreBJMO - volume 6, issue 2, april 2012
V. Morlion , S. Wilgenhof MD, E. Vanderlinden MD, S. Hanon , F. Vandenbroucke , H. Everaert , B. Neyns MD, PhD
A female patient with stage IV-M1c (lymph node and breast metastases), chemorefractory melanoma was treated with the CTLA-4 inhibitory monoclonal antibody ipilimumab. At first evaluation following induction treatment, a marked increase in the volume and strong uptake of 18FDG in her lymphadenopathies (including new adenopathies), a marked enlargement of her spleen and interstitial lung infiltrates were observed. Non-necrotising granulomas were discovered on transbronchial biopsy and cytology on broncho-alveolar lavage established the diagnosis of sarcoidosis. There was a marked clinical and 18FDG-PET/CT documented response following 6 weeks of corticotherapy. At later follow-up, progression of melanoma metastasis in the subdiaphragmatic lymph node metastases was documented. (BELG J MED ONCOL 2012;6:58–62)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
